Mobile Menu
Deals & Transactions

Conyers advises Luye Pharma Group Ltd. on US$764 million IPO

Conyers Dill & Pearman advised Luye Pharma Group Ltd. (“the Company”) on its US$764 million IPO of shares by way of a global offering involving a Hong Kong public offering and international offering. The listing in Hong Kong was the third largest offering in Hong Kong in 2014 and follows its recent privatisation and de-listing from the SGX-ST in November 2012. The Company is involved in developing, producing, marketing and selling innovative pharmaceutical products in three of the largest and fastest growing therapeutic areas in the PRC. The Company's IPO received significant demand pricing at the high end of its indicative range and closing up 13.2% on its offer price. The listing value's the Company at US$3 billion compared to the price at delisting 18 months previously of US$515 million.

Christopher Bickley and Charissa Ball of Conyers’ Hong Kong office advised on the matter, working alongside Ashursts Hong Kong, King & Wood Mallesons, Herbert Smith Freehills LLP and Grandall Law Firm.

 


Christopher W.H. Bickley
Partner, Head of Hong Kong Office

HONG KONG   +852 2842 9556


Charissa Ball
Associate

Hong Kong   +852 2842 9550


Accolades
_

"Few firms can come close to Conyers on one critical metric, and this is the breadth of the client base."
- IFLR1000

expertise

Corporate


Related International Offices

Hong Kong


Media Contact

For media enquiries, please contact media@conyersdill.com

Deals & Transactions

Conyers advises Luye Pharma Group Ltd. on US$764 million IPO

Conyers Dill & Pearman advised Luye Pharma Group Ltd. (“the Company”) on its US$764 million IPO of shares by way of a global offering involving a Hong Kong public offering and international offering. The listing in Hong Kong was the third largest offering in Hong Kong in 2014 and follows its recent privatisation and de-listing from the SGX-ST in November 2012. The Company is involved in developing, producing, marketing and selling innovative pharmaceutical products in three of the largest and fastest growing therapeutic areas in the PRC. The Company's IPO received significant demand pricing at the high end of its indicative range and closing up 13.2% on its offer price. The listing value's the Company at US$3 billion compared to the price at delisting 18 months previously of US$515 million.

Christopher Bickley and Charissa Ball of Conyers’ Hong Kong office advised on the matter, working alongside Ashursts Hong Kong, King & Wood Mallesons, Herbert Smith Freehills LLP and Grandall Law Firm.

 


Christopher W.H. Bickley
Partner, Head of Hong Kong Office

HONG KONG   +852 2842 9556


Charissa Ball
Associate

Hong Kong   +852 2842 9550


 

expertise

Corporate


International Office(s)

Hong Kong